These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27281823)

  • 41. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
    Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
    Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
    Turcotte S; Desrosiers RR; Beliveau R
    Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypoxia-mediated Na-K-ATPase degradation requires von Hippel Lindau protein.
    Zhou G; Dada LA; Chandel NS; Iwai K; Lecuona E; Ciechanover A; Sznajder JI
    FASEB J; 2008 May; 22(5):1335-42. PubMed ID: 18073334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
    Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
    J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intersectin 1 enhances Cbl ubiquitylation of epidermal growth factor receptor through regulation of Sprouty2-Cbl interaction.
    Okur MN; Ooi J; Fong CW; Martinez N; Garcia-Dominguez C; Rojas JM; Guy G; O'Bryan JP
    Mol Cell Biol; 2012 Feb; 32(4):817-25. PubMed ID: 22158968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors.
    Carroll PA; Kenerson HL; Yeung RS; Lagunoff M
    J Virol; 2006 Nov; 80(21):10802-12. PubMed ID: 16956952
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
    An J; Rettig MB
    Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
    Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
    PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential but Complementary HIF1α and HIF2α Transcriptional Regulation.
    Downes NL; Laham-Karam N; Kaikkonen MU; Ylä-Herttuala S
    Mol Ther; 2018 Jul; 26(7):1735-1745. PubMed ID: 29843956
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PHD3 inhibits cell proliferation through hydroxylation of PAX2 at proline 9.
    Lun J; Wang Y; Gao Q; Wang Y; Zhang H; Fang J
    Acta Biochim Biophys Sin (Shanghai); 2022 May; 54(5):708-715. PubMed ID: 35920196
    [TBL] [Abstract][Full Text] [Related]  

  • 54. VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway.
    Shin D; Jeon JH; Jeong M; Suh HW; Kim S; Kim HC; Moon OS; Kim YS; Chung JW; Yoon SR; Kim WH; Choi I
    Biochim Biophys Acta; 2008 May; 1783(5):838-48. PubMed ID: 18062927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. VBP1 represses cancer metastasis by enhancing HIF-1α degradation induced by pVHL.
    Kim JA; Choi DK; Min JS; Kang I; Kim JC; Kim S; Ahn JK
    FEBS J; 2018 Jan; 285(1):115-126. PubMed ID: 29121446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential Contribution of N- and C-Terminal Regions of HIF1α and HIF2α to Their Target Gene Selectivity.
    Bouthelier A; Meléndez-Rodríguez F; Urrutia AA; Aragonés J
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321829
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular cloning and characterization of the von Hippel-Lindau-like protein.
    Qi H; Gervais ML; Li W; DeCaprio JA; Challis JR; Ohh M
    Mol Cancer Res; 2004 Jan; 2(1):43-52. PubMed ID: 14757845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases.
    Paltoglou S; Roberts BJ
    Oncogene; 2007 Jan; 26(4):604-9. PubMed ID: 16862177
    [TBL] [Abstract][Full Text] [Related]  

  • 59. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.
    Roe JS; Kim HR; Hwang IY; Cho EJ; Youn HD
    Oncogene; 2011 Jul; 30(28):3127-38. PubMed ID: 21358672
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.
    Green YS; Sargis T; Reichert EC; Rudasi E; Fuja D; Jonasch E; Koh MY
    Mol Cancer Res; 2019 May; 17(5):1220-1232. PubMed ID: 30705246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.